NCT05386108: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy)

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be off corticosteroids or receiving a stable or decreasing corticosteroid dose at the time of starting trial therapy; Patient must have received prior therapy in the metastatic setting including at least one endocrine therapy, up to two chemotherapy regimens, & up to two prior CDK 4/6 inhibitors (e.g. Ibrance/palbociclib, Kisqali/ribociclib), not including Verzenio/abemaciclib
Exclusions: Patients with leptomeningeal metastases; Patients with prior exposure to elacestrant or Verzenio/abemaciclib in the metastatic setting

Comments are closed.

Up ↑